Objective: To systematically review brain imaging studies in myotonic dystrophy type 1 (DM1).
Therefore, the objective of this study was to provide a comprehensive, widely scoped overview of the substantial body of brain imaging literature in DM1 on 7 commonly used imaging methods (MRI, functional MRI, magnetic resonance spectroscopy [MRS] , ultrasound, SPECT, PET, and CT). In addition, we evaluated the reported relationships between imaging and clinical-genetic parameters in patients with DM1. Finally, we evaluated evidence on temporal changes in DM1 brain imaging (i.e., longitudinal studies) to assess whether these were in support of the view on DM1 as a progressive neurodegenerative disease.
METHODS Search. We searched Embase (index period and MEDLINE (index period 1946-2016) for relevant studies. We searched for free text and index terms related to DM1 and imaging methods (appendix e-1, A and B, at Neurology.org). Our primary search was completed on June 22, 2016, with a final update yielding 3 additional studies performed on September 1, 2016. We also performed crossreferencing to identify articles potentially missed by our search.
Eligibility criteria. We selected studies on the basis of predefined criteria for eligibility, considering studies reporting on patients with DM1 and at least one brain imaging method (appendix e-2). We restricted our selection to studies that used CT, MRI, MRS, SPECT, PET, functional MRI (fMRI), or ultrasound methods. Reasons for exclusion of studies were case reports (on single patients), double reporting, and studies written in a language different from English, French, German, or Dutch. We also excluded studies for which we were unable to obtain full text. Study selection comprised an initial round of title and abstract screening, after which a second round of full-text screening was performed. All (n 5 14) conference abstracts were excluded.
Data extraction. A data extraction form was piloted on 5 studies and consequently adapted where necessary. We extracted clinical information such as age, sex, educational level, types of DM1 (congenital, juvenile, adult-onset), main inclusion and exclusion criteria, and the use of neuropsychological tests and questionnaires for psychiatric disorders. The type of DM1 was arbitrarily defined as presence of first clinical symptoms at birth (congenital myotonic dystrophy type 1 [cDM1]), after birth but before age 18 (juvenile myotonic dystrophy type 1 [jDM1]) or at 18 years or later (adult-onset myotonic dystrophy type 1 [aDM1]). If reported, the estimated age at onset and disease duration were recorded. Furthermore, for each study, we recorded the imaging method used, technical details, and the main findings (see the section on "Data synthesis").
Quality assessment. We adopted a quality assessment form from Kmet et al., with modifications to better suit the requirements of this review (appendix e-3). 4, 5 A single author (K.O.) scored all studies for quality and risk of bias on a scale of 0, 1, or 2 (0 representing the worst and 2 representing the best score).
Data synthesis.
We classified studies by their reporting of either structural or functional imaging data, or both. Structural data comprised structural MRI, CT, and ultrasound studies, whereas fMRI, SPECT, PET, and MRS were classified under functional imaging. For structural MRI studies, we subdivided and separately aggregated data into 3 categories: whole brain (atrophy and/or ventricular enlargement), gray matter (volume; cortical thickness), and white matter (white matter hyperintensities [WMH] and integrity of normal-appearing white matter [NAWM]). We clustered results per brain region (i.e., brain lobes vs deep brain structures and cerebellum; cortical vs subcortical). CT studies were evaluated for information on atrophy (focal or global), ventricular dilatation, and skull hyperostosis. We evaluated ultrasound studies for findings of ventricular dilatation and changes of brainstem echogenicity. Results were assessed in a qualitative manner for all modalities, except for WMH on MRI, which allowed a pooled analysis. We estimated pooled WMH prevalence across brain regions using metaXL (version 5.3; EpiGear International Pty Limited, Queensland, Australia), giving a random-effect weighted mean prevalence with 95% confidence intervals (CIs). We calculated the I 2 statistic as a measure for statistical heterogeneity. For functional imaging studies, aggregation of data was unfeasible due to a limited number of studies per imaging technique and heterogeneous methods.
RESULTS Search and selection results. Our search and selection processes yielded a total of 81 included Abbreviations: ARWMC 5 age-related white matter change scale; DM1 5 myotonic dystrophy type 1; DTI 5 diffusion tensor imaging; FA 5 fractional anisotropy; ROI 5 region of interest; TBSS 5 tract-based spatial statistics; prevalence denotes the ratio of patients with white matter hyperintensity vs total number of patients; TLL and TLA 5 automated methods to detect white matter hyperintensity volume; WMH 5 white matter hyperintensity. MRI studies evaluating whole brain volume/atrophy, gray matter volumes/atrophy, and white matter integrity. For study ID, refer to appendix e-5. a Voxel-based morphometry studies that corrected for age.
Demographics and disease characteristics. Eighty-one studies included a total of 1,663 DM1 cases (appendix e-5A). Twenty-three studies analyzed only DM1 cases, whereas 58 studies included a total of 1,334 unaffected controls. In studies reporting sex, there was an excess of male DM1 cases (865 males [53.4%] vs 754 females [46.6%], x 2 5 7.62, p 5 0.006). The median of average ages across the studies was 38.5 years, interquartile range (IQR) of 5.9 years, and total range of 5-56.6. The median age at onset was 25.7 years (IQR 5.8 years). In 31 studies reporting modal CTG repeat length, median repeat length was 582 repeats (IQR 177 and total range 534-719 repeats). For 27 studies providing information on the muscular impairment rating scale (MIRS), the median score was 3.1 (IQR 0.43), which indicates distal but no proximal weakness. Forty-one imaging studies (51%) performed neuropsychological testing. Regarding disease classification, presence or absence of cDM1, jDM1, and aDM1 was reported in, respectively, 57, 60, and 60 studies. Nineteen studies reported presence of patients with cDM1, whereas patients with jDM1 and aDM1 were included in 48 and 52 studies, respectively. With the exception of MRS, functional imaging studies did not include patients with cDM1. In structural studies, cDM1 participants often comprised a minority of included participants (data not shown).
Quality analysis. Our analysis demonstrated that most studies had a clearly described research question (i.e., score 2, n 5 70), included participants with firmly established diagnosis (both before and after gene identification in 1992) (i.e., score 2, n 5 70), and provided sufficient details on participants characteristics (i.e., score 2, n 5 72), imaging protocol, and analysis (i.e., score 2, n 5 71) (appendix e-5B). Twenty-two studies (27%) provided a full (i.e., score 2) description of the recruitment procedure, and 6 (7%) provided information on the rates of participation. Inclusion and exclusion criteria were provided (i.e., score 1 or 2) in 54 studies (67%); 53 studies took into account (i.e., score 1 or 2) possible confounding factors. We found discussions of study limitations in a minority of the publications included in our review (i.e., score 1 or 2; n 5 27, 33%).
Structural imaging studies. A total of 1,247 DM1 cases and 1,015 healthy controls were included in 65 and 46 structural MRI studies, respectively (summary of outcomes parameters, methods of assessment, and most salient findings in table 2 and figures 1 and 2).
6-30,31-60, e1-e9 Of note, only one MRI study had a longitudinal design. 18 Whole brain. Irrespective of the method of analysis, the large majority of studies found generalized atrophy in DM1 participants compared with healthy controls (table 2) .
Gray matter. Gray matter volumes were mostly assessed with semiautomated or fully automated methods (voxel-based morphometry [VBM]) (table 2) . Nine studies used VBM in DM1, showing a pattern of widespread reduction of gray matter volume in DM1 cases compared with controls. Reduction of gray matter volume was found in frontal (n 5 9 of 9), temporal (n 5 7 of 9), parietal (n 5 8 of 9), and occipital cortices (n 5 7 of 9), as well as to deep gray matter structures (n 5 8 of 9) and cerebellum (n 5 3 of 4). The data did not allow for analyses of atrophy in areas within lobes, or within specific deep gray matter structures. Comparing cortical thickness between DM1 and control brains (n 5 1 study comprising 24 patients), reduced cortical thickness was demonstrated in parietal-occipital cortex bilaterally, as well as in the unilateral (left or right) frontal and temporal cortex. White matter. We calculated the pooled prevalence (pp) of WMH across 49 studies that provided sufficient data for analysis. We found a pp of 70.4% (95% CI 5 63.8-76.5%), with substantial statistical heterogeneity (I 2 5 77%). Fifteen studies also reported the prevalence of white matter hyperintensities in (age-and sex-matched) controls, with a pp of 6.4% (95% CI 5 2.5-11.7%). WMH in patients with DM1 were located in periventricular and subcortical white matter, preferentially in frontal (pp 52%, 95% CI 5 38-65%, I 2 5 54%), temporal (pp 44%, 95% CI 5 31-58%, I 2 5 49%), and parietal lobes (pp 31%, 95% CI 5 23-40%, I
2 5 12%), although they were also noted to occur in the occipital lobe in 8 studies. Anterior temporal pole (i.e., "deep temporal"; figure 2) WMH were reported in 12 studies, of which 10 provided sufficient information to calculate a pp of 30.3% (95% CI 5 17.3%-45.0%; I 2 5 82%). WMH volume/lesion load across studies was difficult to aggregate because of differences in methodology and reporting (summarized in appendix e-6). Besides WMH, enlarged Virchow-Robin spaces were shown to be more prevalent in DM1 cases than in unaffected controls in 4 studies (data not shown).
The structural integrity of the NAWM was mostly evaluated by means of diffusion tensor imaging (table 2) . Studies used region-of-interest (ROI) approaches and tract-based spatial statistics (TBSS) demonstrated widespread reduction of fractional anisotropy (FA) and increase in mean diffusivity in patients with DM1 compared with controls. Specifically, ROI approaches demonstrated FA reduction in all 4 lobes and some predefined fiber tracts (e.g., inferior and superior longitudinal fasciculus, uncinate fasciculus, forceps minor and major, cingulum). TBSS studies showed mostly symmetrical decreased FA in all major association, projection, and commissural fibers.
Ten CT studies (1983-2013) included a total of 162 DM1 cases and 122 unaffected individuals. 12,58, e10-e17 These studies focused on the presence of ventricular dilatation (present in 1 of 19 to 6 of 7 patients), general atrophy (present in 3 of 19 to 22 of 37 patients), and frontal hyperostosis (10 of 37 to 14 of 16 patients). Two uncontrolled ultrasound studies examined 24 newborn patients with congenital DM1 and found ventricular dilatation and macrocephaly in the majority of patients (11 of 14 and 8 of 10, respectively). e18, e19 Two ultrasound studies reported increased third ventricle diameter and mixed results for brainstem echogenicity in (mostly) adult DM1 cases vs controls. 41, e20 Functional imaging studies. Seven PET studies demonstrated a consistent global decrease in glucose uptake and regional reductions (i.e., lobe specific) compared with unaffected controls (table 3) . 45 , e3, e9, e21-e24 Controlling for possible volumetric differences in 2 of these studies did not alter the results. e3, e9 Five SPECT studies demonstrated a picture in line with findings from PET studies, demonstrating both global and regional decreases (i.e., lobe specific) in cerebral perfusion in DM1 cases compared with unaffected controls (table 3) . 16,53,60, e24, e25 In fMRI studies, an altered activation pattern in bilateral motor regions was demonstrated in patients with DM1 during a motor task and in the presence of clinical myotonia. 13, e26 Abnormal resting-state functional connectivity in defaultmode and "theory-of-mind" networks was also noted in relation to personality traits and social cognition in DM1 (table 3) . 56, e27 The most consistent finding in MRS studies was a decrease in N-acetylaspartate (NAA) (table 4).
8,17,35, e2, e28
Correlation of imaging with genetic and clinical parameters. Twenty-seven studies examined a total of 53 correlations between imaging findings and modal CTG repeat length in blood, with 15 significant correlations found in 10 studies (appendix e-7A). In general, longer CTG repeats were associated with greater structural and functional changes of the brain. However, variations in imaging modalities and statistical tests (e.g., linear regression, parametric, or nonparametric correlation coefficients) limited comparisons between studies. We found correlational analyses between imaging findings with age and duration of disease in 28 and 27 studies, totaling 43 and 45 associations, respectively (appendix e-7, B and C). Significant simple (i.e., Pearson or nonparametric equivalent) correlations for age (16 of 43) and disease duration (20 of 45) with imaging changes ranged from small (;0.3) to strong (;0.7) and most frequently concerned white matter lesions. Evaluation of correlations with neuropsychological testing failed to yield consistent relationships (appendix e-7D). For example, neuropsychological studies in DM1 have shown consistent deficits on visuoconstruction domain as demonstrated by the Rey-Osterrieth Complex Figure Copy Test (ROCF-C) (authors' data, unpublished). However, only 3 of 15 correlational analyses using the ROCF-R found significant correlations between imaging findings and tests results (appendix e-7D).
11,53
DISCUSSION In DM1, there is a broad spectrum of imaging changes that are widely dispersed throughout the brain, with apparently little anatomical specificity. Our findings are in line with the wide range of clinical, molecular, and histopathologic brain alterations Table 3 Functional imaging studies in myotonic dystrophy type 1 previously reported. e29, e30 Significant between-study heterogeneity in terms of imaging methods, together with the established clinical variability of DM1, may explain divergent results. At the structural level, we found evidence for general brain atrophy, which corroborates histopathology studies demonstrating diffuse cerebral atrophy.
e31, e32 Partly, brain atrophy can be attributed to volume loss of gray matter, which is evident in all lobes, deep gray matter, and cerebellum in VBM studies. Notably, VBM is best suited for the evaluation of cortical changes, less so for deep gray matter structures for reasons mainly related to tissue segmentation. e33, e34 In addition, the cerebellum is often not analyzed in VBM studies. Also, age factor, corrected in 5 of 9 studies, may have influenced the results. Possible explanations for gray matter volume loss are speculative, but may include neuronal loss and loss and/or decreased genesis of dendritic spines and synapses.
e32, e35 The possibility of neuronal loss is corroborated by MRS studies that show decreases in [NAA] in gray matter, a marker for neuronal density.
White matter involvement in DM1 involves T2/ fluid-attenuated inversion recovery (FLAIR) hyperintensities preferentially located in frontal, temporal, and parietal lobes at periventricular and subcortical locations. Compared with matched healthy controls, patients with DM1 have a higher frequency of WMH. The temporo-polar WMH, reported to be relatively specific for DM1, is present in approximately one-third of patients. Divergent prevalence (70.4% [95% CI 5 63.8-76.5%]; I 2 5 77%) of WMH across studies may be the result of study characteristics such as field strength (e.g., 1.5 vs 3 T), imaging sequence (e.g., T2 vs FLAIR), voxel-sizes, and other methodological parameters.
e36 Of note, differences between studies might relate to variations between study populations in terms of age, DM1 disease class and severity, and CTG repeat length. Besides WMH, there is now substantial evidence for diffuse involvement of NAWM, as mainly demonstrated by DTI techniques. Notably, all DTI studies used a similar method of controlling for family-wise error at the p , 0.05 threshold. Future studies applying more stringent thresholding might theoretically uncover a more focal pattern of white matter involvement. Nonetheless, it is likely that damage to structural brain networks results in alterations in functional connectivity that has recently been demonstrated in DM1. 56, e27 These studies are critically important for better understanding of imaging correlates of neuropsychological involvement in DM1. The lack of consistent correlations found to date may result from limited power due to small sample sizes and from the fact that cognitive functions are not anatomically set to one particular brain region, but rather are a consequence of complex network interactions.
e37
With regard to the etiology of white matter damage, we cannot exclude a role for "traditional" vascular risk factors as less than half of the studies took into account these confounders, and some risk factors (e.g., smoking and hypercholesterolemia) have been shown to be highly prevalent in DM1. e38, e39 However, the presence of temporal and temporopolar WMH argues against a solely cardiovascular etiology of WMH in DM1. The pattern of WMH concurs with the predominantly frontal, temporal, and parietal anomalies observed with PET and SPECT imaging, suggesting a possible role for decreased perfusion in the etiology of WMH. An important caveat is the fact that none of the SPECT and only 2 of the 7 PET studies corrected for atrophy. Nevertheless, these studies are notable for the fact that changes in frontal perfusion corroborate clinical frontal lobe involvement, such as apathy and disorders of executive functioning. 3 It remains speculative whether perfusion deficits are a cause or consequence in DM1 pathophysiology: neuronal dysfunction/loss may lead to decreased metabolic demands; alternatively perfusion deficits may be causal to tissue damage and dysfunction.
The paucity of longitudinal imaging studies (3 of 81) in DM1 is striking given the chronic nature and relatively long survival in the disease and especially because many of the neuroimaging findings discussed in this study (e.g., brain atrophy and WMH) are associated with age in the general population.
e40-e42
Whether imaging anomalies in DM1 have a specific spatiotemporal pattern (i.e., start in certain anatomical region(s) and disseminate over the brain with time) should be tested in future studies. Such progressive nature of brain involvement in DM1 is suggested by neuropsychological studies documenting cognitive decline in some (e.g., attention, psychomotor speed and executive functions) but not all cognitive domains over many months to years. e43, e44 Complex interrelations between clinical and genetic parameters may explain the lack of an effect of age, disease duration, and length of repeat on neuroimaging findings one would expect in a neurodegenerative disease. Anticipation in DM1 is extreme, with age at onset typically decreasing by 20-30 years per generation. e45 Coupled with the sex-dependent mutational dynamics, anticipation in DM1 leads to a family structure that is highly nonrandom in terms of age, inherited CTG repeat length, and disease severity.
e45-e48
Thus, individuals recruited from the first generation of known DM1 families have only a mild presentation of disease despite the fact that they are usually relatively old before the disease is diagnosed in their family. Conversely, individuals from later generations, despite being younger, usually have inherited a much larger CTG repeat and thus present with a more severe form of the disease. As a result, the true effects of age and inherited CTG length are masked by their inverse relationship in the patient population. Moreover, somatic instability of the DMPK CTG repeat that is age-and tissuedependent and expansion-biased could lead to longer modal CTG repeats in blood DNA of older individuals and have a negative effect on the precision of genotype-phenotype relationships.
e49-e52 The CTG repeat is also somatically unstable in other tissues, including postmitotic tissues (e.g., brain), and it has been suggested that somatic expansion may contribute, at least in part, to the tissue specificity and progressive nature of the symptoms.
e49-e52 It should be noted that with the exception of cerebellum, average CTG repeat lengths are thousands of repeats longer than the inherited allele length in various regions of the brain.
e32, e53, e54 Thus, it may not be surprising that pathology in the DM1 brain is widespread and diffuse.
Limitations and future directions. Our study has several limitations. A single author performed literature search and selection. Although we also performed cross-referencing by 2 authors, we cannot exclude the possibility of missed studies. Selection preferences of reviewed studies may have biased recruitment toward participants with obvious CNS involvement or away from individuals with apathy, thus limiting the generalizability of our findings. Moreover, selection preferences and the sampling biases discussed earlier preclude the identification of relevant differential phenotypes in the DM1 population that could help to explain heterogeneity in our results. The latter is also impeded by the absence of a universally accepted and adopted disease classification (e.g., congenital, childhood, juvenile, adult, and late-onset DM1) across studies.
Our study underlines the need for a large, imaging study of long duration (i.e., preferably $10 years) including genetically and clinically well characterized participants. Ideally, recruitment and source of participants would be carefully described and potential sources of confounding (e.g., vascular risk factors) accounted for. International collaboration, as exemplified by the European OPTIMISTIC trial in DM1, will increase generalizability of results and statistical power.
e55 Such a study will not only provide better insight into natural history but also allow to determine which imaging parameters are suitable as outcome markers in future clinical trials.
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